Navigating breast cancer: Axon guidance molecules as breast cancer tumor suppressors and oncogenes

Journal of Mammary Gland Biology and Neoplasia

Volumn 16, Issue 3, 2011, Pages 257-270

  Harburg, Gwyndolen C ^a   Hinck, Lindsay ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Axon guidance molecules; Ephrin; Netrin; Robo; Semaphorin; Slit

Indexed keywords

CYTOTOXIN; EPHRIN; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; IMATINIB; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NETRIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SEMAPHORIN; SLIT2 PROTEIN; SMALL INTERFERING RNA; TAMOXIFEN; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AXON GUIDANCE MOLECULE; BINDING SITE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CELL ADHESION; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; LIGAND BINDING; MAMMARY GLAND; MOLECULE; MORPHOGENESIS; NONHUMAN; ONCOGENE; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; AXONS; BREAST NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; SEMAPHORINS;

EID: 80053566650     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-011-9225-1     Document Type: Article

References (91)

1. Dickson BJ. Molecular mechanisms of axon guidance. Science. 2002;298(5600):1959-64. doi: 10.1126/science.1072165. (Pubitemid 35425245)
2. Hinck L. The versatile roles of "axon guidance" cues in tissue morphogenesis. Dev Cell. 2004;7(6):783-93. doi:10.1016/j.devcel.2004.11.002. (Pubitemid 39654724)
3. Mehlen P, Delloye-Bourgeois C, Chedotal A. Novel roles for Slits and netrins: axon guidance cues as anticancer targets? Nat Rev Cancer. 2011;11(3):188-97. doi:10.1038/nrc3005.
4. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer. 2008;8(8):632-45. doi:10.1038/nrc2404.
5. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10(3):165-80. doi:10.1038/nrc2806.
6. Strickland P, Shin GC, Plump A, Tessier-Lavigne M, Hinck L. Slit2 and netrin 1 act synergistically as adhesive cues to generate tubular bi-layers during ductal morphogenesis. Development. 2006;133(5):823-32. doi:10.1242/dev. 02261.
7. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2008;118(1):64-78. doi:10.1172/JCI33154.
8. Munarini N, Jager R, Abderhalden S, Zuercher G, Rohrbach V, Loercher S, et al. Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J Cell Sci. 2002;115(Pt 1):25-37. (Pubitemid 34105526)
9. Haldimann M, Custer D, Munarini N, Stirnimann C, Zurcher G, Rohrbach V, et al. Deregulated ephrin-B2 expression in the mammary gland interferes with the development of both the glandular epithelium and vasculature and promotes metastasis formation. Int J Oncol. 2009;35(3):525-36.
10. Marlow R, Strickland P, Lee JS, Wu X, Pebenito M, Binnewies M, et al. SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. Cancer Res. 2008;68(19):7819-27. doi:10.1158/0008-5472. CAN-08-1357.
11. Srinivasan K, Strickland P, Valdes A, Shin GC, Hinck L. Netrin-1/neogenin interaction stabilizes multipotent progenitor cap cells during mammary gland morphogenesis. Dev Cell. 2003;4(3):371-82. (Pubitemid 36342362)
12. Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, et al. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res. 2002;62(20):5874-80. (Pubitemid 35204748)
13. Dickinson RE, Dallol A, Bieche I, Krex D, Morton D, Maher ER, et al. Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer. 2004;91(12):2071-8. doi:10.1038/sj.bjc.6602222. (Pubitemid 40128774)
14. Dallol A, Forgacs E, Martinez A, Sekido Y, Walker R, Kishida T, et al. Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers. Oncogene. 2002;21(19):3020-8. doi:10.1038/sj.onc.1205421. (Pubitemid 34522901)
15. Macias H, Moran A, Samara Y, Moreno M, Compton JE, Harburg G, et al. SLIT/ROBO1 signaling suppresses mammary branching morphogenesis by limiting basal cell number. Dev Cell. 2011;20(6):827-40. doi:10.1016/j.devcel.2011.05. 012.
16. Prasad A, Paruchuri V, Preet A, Latif F, Ganju RK. Slit-2 induces a tumor-suppressive effect by regulating beta-catenin in breast cancer cells. J Biol Chem. 2008;283(39):26624-33. doi:10.1074/jbc. M800679200.
17. Yuasa-Kawada J, Kinoshita-Kawada M, Rao Y, Wu JY. Deubiquitinating enzyme USP33/VDU1 is required for Slit signaling in inhibiting breast cancer cell migration. Proc Natl Acad Sci USA. 2009;106(34):14530-5. doi:10.1073/pnas. 0801262106.
18. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50-6. doi:10.1038/35065016. (Pubitemid 32225831)
19. Schmid BC, Rudas M, Rezniczek GA, Leodolter S, Zeillinger R. CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. Breast Cancer Res Treat. 2004;84(3):247-50. doi:10.1023/B:BREA. 0000019962.18922.87. (Pubitemid 38445374)
20. Prasad A, Fernandis AZ, Rao Y, Ganju RK. Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells. J Biol Chem. 2004;279(10):9115-24. doi:10.1074/jbc. M308083200. (Pubitemid 38295976)
21. Wu JY, Feng L, Park HT, Havlioglu N, Wen L, Tang H, et al. The neuronal repellent Slit inhibits leukocyte chemotaxis induced by chemotactic factors. Nature. 2001;410(6831):948-52. doi:10.1038/35073616. (Pubitemid 32335842)
22. Llambi F, Causeret F, Bloch-Gallego E, Mehlen P. Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. EMBO J. 2001;20(11):2715-22. doi:10.1093/emboj/20.11.2715. (Pubitemid 32938556)
23. Fitamant J, Guenebeaud C, Coissieux MM, Guix C, Treilleux I, Scoazec JY, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci USA. 2008;105(12):4850-5. doi:10.1073/pnas.0709810105. (Pubitemid 351753835)
24. Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, et al. Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature. 1997;386(6627):796-804. doi:10.1038/386796a0. (Pubitemid 27181247)
25. Thiebault K, Mazelin L, Pays L, Llambi F, Joly MO, Scoazec JY, et al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc Natl Acad Sci USA. 2003;100(7):4173-8. doi:10.1073/pnas. 0738063100. (Pubitemid 36418176)
26. Lee JE, Kim HJ, Bae JY, Kim SW, Park JS, Shin HJ, et al. Neogenin expression may be inversely correlated to the tumorigenicity of human breast cancer. BMC Cancer. 2005;5:154. doi:10.1186/1471-2407-5-154. (Pubitemid 41800228)
27. Nacht M, St Martin TB, Byrne A, Klinger KW, Teicher BA, Madden SL, et al. Netrin-4 regulates angiogenic responses and tumor cell growth. Exp Cell Res. 2009;315(5):784-94. doi:10.1016/j.yexcr.2008.11.018.
28. Qin S, Yu L, Gao Y, Zhou R, Zhang C. Characterization of the receptors for axon guidance factor netrin-4 and identification of the binding domains. Mol Cell Neurosci. 2007;34(2):243-50. doi:10.1016/j.mcn. 2006.11.002. (Pubitemid 46136998)
29. Lejmi E, Leconte L, Pedron-Mazoyer S, Ropert S, Raoul W, Lavalette S, et al. Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B. Proc Natl Acad Sci USA. 2008;105(34):12491-6. doi:10.1073/pnas. 0804008105.
30. Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS, et al. Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res. 2007;13(11):3164-73. doi:10.1158/1078-0432. CCR-07-0224. (Pubitemid 46944898)
31. Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, et al. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Treat. 2010;122(3):699-710. doi:10.1007/s10549-009-0600-1.
32. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA. 2004;101(15):5583-8. doi:10.1073/pnas.0401381101. (Pubitemid 38481199)
33. Walker-Daniels J, Riese 2nd DJ, Kinch MS. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res. 2002;1(1):79-87. (Pubitemid 36330213)
34. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001;61(5):2301-6. (Pubitemid 32692063)
35. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, et al. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther. 2004;11(11):757-66. doi:10.1038/sj.cgt.7700761. (Pubitemid 39488474)
36. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell. 2005;8(2):111-8. doi:10.1016/j.ccr.2005.07.005. (Pubitemid 41132740)
37. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ. 1999;10(9):629-38. (Pubitemid 29455727)
38. Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene. 2008;27(58):7260-73. doi:10.1038/onc.2008.328.
39. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J. 2005;19(13):1884-6. doi:10.1096/fj.05-4038fje. (Pubitemid 41598783)
40. Gokmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C et al. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res Treat. 2010. doi:10.1007/s10549-010-1004-y.
41. Hiramoto-Yamaki N, Takeuchi S, Ueda S, Harada K, Fujimoto S, Negishi M, et al. Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism. J Cell Biol. 2010;190(3):461-77. doi:10.1083/jcb.201005141.
42. Zelinski DP, Zantek ND, Walker-Daniels J, Peters MA, Taparowsky EJ, Kinch MS. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase. J Cell Biochem. 2002;85(4):714-20. doi:10.1002/jcb.10186. (Pubitemid 34462782)
43. Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 2003;63(12):3425-9. (Pubitemid 36735904)
44. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006;169(1):279-93. doi:10.2353/ajpath.2006.050889.
45. Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol. 2006;8(8):815-25. doi:10.1038/ncb1438. (Pubitemid 44151584)
46. Nikolova Z, Djonov V, Zuercher G, Andres AC, Ziemiecki A. Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J Cell Sci. 1998;111(Pt 18):2741-51. (Pubitemid 28479198)
47. Berclaz G, Andres AC, Albrecht D, Dreher E, Ziemiecki A, Gusterson BA, et al. Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium. Biochem Biophys Res Commun. 1996;226(3):869-75. doi:10.1006/bbrc.1996.1442. (Pubitemid 26348561)
48. Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res. 2004;10(1):26-33. doi:PAOR.2004.10.1.0026. (Pubitemid 38506609)
49. Kaenel P, Schwab C, Mulchi K, Wotzkow C, Andres AC. Preponderance of cells with stem cell characteristics in metastasising mouse mammary tumours induced by deregulated EphB4 and ephrin-B2 expression. Int J Oncol. 2011;38(1):151-60.
50. Lee HS, Nishanian TG, Mood K, Bong YS, Daar IO. EphrinB1 controls cell-cell junctions through the Par polarity complex. Nat Cell Biol. 2008;10(8):979-86. doi:10.1038/ncb1758.
51. Lee HS, Daar IO. EphrinB reverse signaling in cell-cell adhesion: is it just par for the course? Cell Adh Migr. 2009;3(3):250-5.
52. Gu C, Limberg BJ, Whitaker GB, Perman B, Leahy DJ, Rosenbaum JS, et al. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem. 2002;277(20):18069-76. doi:10.1074/jbc. M201681200. (Pubitemid 34967620)
53. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci USA. 2007;104(15):6152-7. doi:10.1073/pnas.0700043104. (Pubitemid 47186064)
54. Appleton BA, Wu P, Maloney J, Yin J, Liang WC, Stawicki S, et al. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J. 2007;26(23):4902-12. doi:10.1038/sj.emboj. 7601906. (Pubitemid 350191304)
55. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001;61(15):5736-40. (Pubitemid 32769088)
56. Castro-Rivera E, Ran S, Brekken RA, Minna JD. Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. Cancer Res. 2008;68(20):8295-303. doi:10.1158/0008-5472. CAN-07-6601.
57. Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA. 2004;101(31):11432-7. doi:10.1073/pnas. 0403969101. (Pubitemid 39038364)
58. Pan H, Wanami LS, Dissanayake TR, Bachelder RE. Autocrine semaphorin3A stimulates alpha2 beta1 integrin expression/function in breast tumor cells. Breast Cancer Res Treat. 2009;118(1):197-205. doi:10.1007/s10549-008-0179-y.
59. Nasarre P, Constantin B, Rouhaud L, Harnois T, Raymond G, Drabkin HA, et al. Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia. 2003;5(1):83-92. (Pubitemid 36151061)
60. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, et al. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia. 2005;7(2):180-9. doi:10.1593/neo.04481. (Pubitemid 40315995)
61. Rolny C, Capparuccia L, Casazza A, Mazzone M, Vallario A, Cignetti A, et al. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med. 2008;205(5):1155-71. doi:10.1084/jem.20072509. (Pubitemid 351679690)
62. Esselens C, Malapeira J, Colome N, Casal C, Rodriguez-Manzaneque JC, Canals F, et al. The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J Biol Chem. 2010;285(4):2463-73. doi:10.1074/jbc. M109.055129.
63. Basile JR, Castilho RM, Williams VP, Gutkind JS. Semaphorin 4D provides a link between axon guidance processes and tumorinduced angiogenesis. Proc Natl Acad Sci USA. 2006;103(24):9017-22. doi:10.1073/pnas.0508825103. (Pubitemid 43902525)
64. Swiercz JM, Worzfeld T, Offermanns S. ErbB-2 and met reciprocally regulate cellular signaling via plexin-B1. J Biol Chem. 2008;283(4):1893-901. doi:10.1074/jbc. M706822200.
65. Ramesh G, Berg A, Jayakumar C. Plasma netrin-1 is a diagnostic biomarker of human cancers. Biomarkers. 2011;16(2):172-80. doi:10.3109/1354750X.2010. 541564.
66. Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci. 2007;80(20):1873-81. doi:10.1016/j.lfs. 2007.02.026. (Pubitemid 46562520)
67. Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther. 2007;6(12 Pt 1):3208-18. doi:10.1158/1535-7163. MCT-07-0200.
68. Mille F, Llambi F, Guix C, Delloye-Bourgeois C, Guenebeaud C, Castro-Obregon S, et al. Interfering with multimerization of netrin-1 receptors triggers tumor cell death. Cell Death Differ. 2009;16(10):1344-51. doi:10.1038/cdd.2009.75.
69. Ho KY, Kalle WH, Lo TH, Lam WY, Tang CM. Reduced expression of APC and DCC gene protein in breast cancer. Histopathology. 1999;35(3):249-56. (Pubitemid 29468959)
70. Vaught D, Chen J, Brantley-Sieders DM. Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol Biol Cell. 2009;20(10):2572-81. doi:10.1091/mbc. E08-04-0378.
71. Kouros-Mehr H, Werb Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn. 2006;235(12):3404-12. doi:10.1002/dvdy.20978. (Pubitemid 44888206)
72. Chodosh LA, Gardner HP, Rajan JV, Stairs DB, Marquis ST, Leder PA. Protein kinase expression during murine mammary development. Dev Biol. 2000;219(2):259-76. doi:10.1006/dbio.2000.9614. (Pubitemid 30152604)
73. Fox BP, Kandpal RP. EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. Oncogene. 2009;28(14):1706-13. doi:10.1038/onc.2009.18.
74. Morris JS, Stein T, Pringle MA, Davies CR, Weber-Hall S, Ferrier RK, et al. Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary gland. J Cell Physiol. 2006;206(1):16-24. doi:10.1002/jcp. 20427. (Pubitemid 41740713)
75. Xiang RH, Hensel CH, Garcia DK, Carlson HC, Kok K, Daly MC, et al. Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics. 1996;32(1):39-48. doi:10.1006/geno. 1996.0074.
76. Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in postlactational regression. Breast Cancer Res. 2004;6(2):R92-R109. doi:10.1186/bcr754.
77. Qu X, Wei H, Zhai Y, Que H, Chen Q, Tang F, et al. Identification, characterization, and functional study of the two novel human members of the semaphorin gene family. J Biol Chem. 2002;277(38):35574-85. doi:10.1074/jbc. M206451200.
78. Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ, et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res. 2003;63(17):5230-3. (Pubitemid 37139833)
79. Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, et al. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res. 2007;13(4):1115-22. doi:10.1158/1078-0432. CCR-06-2433. (Pubitemid 46424050)
80. Schmid BC, Rezniczek GA, Fabjani G, Yoneda T, Leodolter S, Zeillinger R. The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat. 2007;106(3):333-42. doi:10.1007/s10549-007-9504-0. (Pubitemid 350029681)
81. Sundaresan V, Chung G, Heppell-Parton A, Xiong J, Grundy C, Roberts I, et al. Homozygous deletions at 3p12 in breast and lung cancer. Oncogene. 1998;17(13):1723-9. doi:10.1038/sj.onc.1202103. (Pubitemid 28482649)
82. Kashiwaba M, Tamura G, Ishida M. Frequent loss of heterozygosity at the deleted in colorectal carcinoma gene locus and its association with histologic phenotypes in breast carcinoma. Virchows Arch. 1995;426(5):441-6.
83. Reale MA, Hu G, Zafar AI, Getzenberg RH, Levine SM, Fearon ER. Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues. Cancer Res. 1994;54(16):4493-501. (Pubitemid 24273168)
84. Thompson AM, Morris RG, Wallace M, Wyllie AH, Steel CM, Carter DC. Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. Br J Cancer. 1993;68(1):64-8. (Pubitemid 23178552)
85. Wakita K, Kohno N, Sakoda Y, Ishikawa Y, Sakaue M. Decreased expression of the DCC gene in human breast carcinoma. Surg Today. 1996;26(11):900-3. (Pubitemid 26389164)
86. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene. 2000;19(52):6043-52. doi:10.1038/sj.onc.1204004. (Pubitemid 32039378)
87. Somiari SB, Shriver CD, He J, Parikh K, Jordan R, Hooke J, et al. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. Cancer Genet Cytogenet. 2004;155(2):108-18. doi:10.1016/j.cancergencyto.2004.02.023. (Pubitemid 39574920)
88. Fox BP, Kandpal RP. DNA-based assay for EPHB6 expression in breast carcinoma cells as a potential diagnostic test for detecting tumor cells in circulation. Cancer Genomics Proteomics. 2010;7(1):9-16.
89. Fox BP, Kandpal RP. Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR. Biochem Biophys Res Commun. 2006;340(1):268-76. doi:10.1016/j.bbrc.2005.11.174. (Pubitemid 41827676)
90. Christensen C, Ambartsumian N, Gilestro G, Thomsen B, Comoglio P, Tamagnone L, et al. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res. 2005;65(14):6167-77. doi:10.1158/0008-5472. CAN-04-4309. (Pubitemid 40994402)
91. Rody A, Karn T, Ruckhaberle E, Hanker L, Metzler D, Muller V, et al. Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers-results of a large scale microarray analysis. Eur J Cancer. 2009;45(3):405-13. doi:10.1016/j.ejca.2008.10.016.